Ashland reports preliminary financial results for fourth quarter of fiscal 2017
Monday, November 06, 2017 5:18:47 PM ET
Company drives strong sales and earnings growth, provides fiscal 2018 financial outlook
COVINGTON, KY, November 6, 2017 - Ashland Global Holdings Inc. (ASH ), a premier global specialty chemicals company serving customers in a wide range of consumer and industrial markets, today announced preliminary(1) financial results for the fourth quarter of fiscal 2017:
- Sales grew 17 percent year-over-year to $880 million.
- Reported net loss was $58 million, while loss from continuing operations was $53 million, or $0.84 per diluted share;
- On an adjusted basis, income from continuing operations was $50 million, or $0.78 per diluted share.
- Adjusted EBITDA was $161 million.
"In the fourth quarter, the Ashland team delivered year-over-year sales gains and strong earnings growth across all three segments," said William A. Wulfsohn, Ashland chairman and chief executive officer.
"Within Specialty Ingredients, Pharmachem contributed strong results. Additionally, excluding Pharmachem, adjusted EBITDA growth was driven by five percent gross profit improvement in the business through focused execution on our asset utilization effort. Within Composites, the team did a great job of generating sales and earnings growth by driving higher volume across all regions and taking action to raise prices in the face of higher raw-material costs. Within Intermediates and Solvents, the team delivered significant increases in adjusted EBITDA and EBITDA margin through pricing discipline amid healthy global demand."
Reportable Segment Performance and Outlook
To aid in the understanding of Ashlands ongoing business performance, the results of Ashlands reportable segments are described below on an adjusted basis and EBITDA, or adjusted EBITDA, is reconciled to operating income in Table 7 of this news release. In addition, free cash flow is reconciled in Table 6 and adjusted earnings per share is reconciled in Table 8 of this news release. (For a more detailed review of the segment results, please refer to the Investor Relations section of ashland.com to review the slides filed with the Securities and Exchange Commission in conjunction with this earnings release.) In addition, although Ashland provides forward-looking guidance for adjusted EBITDA, free cash flow and adjusted earnings per share, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP-reported financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable U.S. GAAP measure because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items that affect these metrics such as domestic and international economic, political, legislative, regulatory and legal actions. In addition, certain economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies and changes in the prices of certain key raw materials, can have a significant effect on operations and are difficult to predict with certainty.
- Sales increased 12 percent, to $598 million, driven primarily by the contribution from Pharmachem and sales growth in personal care and pharmaceutical end markets. Adhesives and coatings sales were flat as the team worked to drive pricing.
- Better asset utilization and reduced plant spend drove a 150-basis-point improvement in gross profit.
- Selling, General and Administrative (SG&A) costs rose, driven primarily by the Pharmachem acquisition.
- Adjusted EBITDA grew 12 percent, driven by both Pharmachem and growth in the balance of the base business.
- Sales climbed 35 percent, to $219 million, as the team generated strong organic growth from continued pricing discipline through an ongoing focus on commercial excellence and value selling, as well as gains in all key end markets and regions.
- Adjusted EBITDA grew 64 percent and adjusted EBITDA margin climbed 190 basis points.
Intermediates & Solvents
- Sales increased 5 percent, to $63 million, driven by strong pricing and continued healthy market demand.
- Adjusted EBITDA grew from $3 million to $10 million.
Balance Sheet and Cash Flow
- Total debt was $2.8 billion.
- Net debt was $2.3 billion.
- During the quarter, cash provided by operating activities totaled $140 million and free cash flow was $67 million.
The company also issued its financial outlook for fiscal 2018 as shown in the table below.
- Specialty Ingredients $560 - $590 million
- Composites $85 - $95 million
- Intermediates & Solvents $40 - $50 million
- Unallocated and other ($35 - $45 million)
Key Operating Metrics
- Free cash flow >$220 million
- Adjusted earnings per share (EPS) $3.20 - $3.40*
- Depreciation & amortization $290 million
- Interest expense $125 - $135 million
- Effective tax rate 8 - 13%
- Capital expenditures $195 - $205 million
- Diluted share count 64 million
*For fiscal 2017, loss from continuing operations per diluted share was $1.69 and adjusted earnings from continuing operations per diluted share was $2.44.
For the first quarter of fiscal 2018, Ashland expects adjusted earnings in the range of $0.35-$0.45 per diluted share, compared to $0.14 in the prior-year period. This estimate assumes an effective tax rate of 10 percent.
"At Ashlands investor day in May, we outlined seven core levers to drive sales and earnings growth in fiscal 2018 and beyond. These levers include specific actions to sustain and grow Ashlands premium mix, such as through new market strategies and successful product introductions. The levers also include new initiatives to improve our competitiveness, such as through better asset utilization, price-to-value initiatives and cost management," Wulfsohn said.
"We are beginning to see the positive impact from these actions. Our sharpened focus on asset utilization is generating good improvement in gross profit. The addition of Pharmachem has contributed strong results while opening new opportunities in nutraceutical, food and fragrance markets. We recently added production capacity in pharma and expect to return to historical growth rates going forward. We expect adhesives and coatings to return to growth in the first half of fiscal 2018, and we are seeing early indications of that in our October results. We have introduced 23 new products over the past year, including a premium hair care product that won best functional ingredient at a major cosmetics trade show in London. We also filed 22 patent applications over the same period as part of our ongoing investment in innovation. Our manufacturing teams are driving better asset utilization through reduced plant spend and increased plant absorption. At the same time, our sales teams have been focused on better articulating the value we provide for our customers and then capturing that value in price.
"In summary, Ashland has a clear strategy to drive strong sales and earnings growth. The aggressive, concrete actions we have taken to improve our business are building good momentum as we enter fiscal 2018, as reflected in our forecast for 30 to 40 percent growth in adjusted earnings per share for the full year," Wulfsohn said.
For additional information on Ashlands fourth-quarter financial results, please see the slide presentation accompanying this news release.
Conference Call Webcast
Ashland will host a live webcast of its fourth-quarter conference call with securities analysts at 9 a.m. EST Tuesday, November 7, 2017. The webcast will be accessible through Ashlands website at http://investor.ashland.com . Following the live event, an archived version of the webcast and supporting materials will be available for 12 months.
Use of Non-GAAP Measures
Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA and Adjusted EBITDA provide Ashlands investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income and operating income. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA and Adjusted EBITDA exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA and Adjusted EBITDA provide disclosure on the same basis as that used by Ashlands management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashlands historical operating performance and its business units and provide continuity to investors for comparability purposes.
The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, free cash flow includes the impact of capital expenditures from continuing operations, providing a more complete picture of cash generation. Free cash flow has certain limitations, including that it does not reflect adjustment for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.
Adjusted earnings per share is a performance measure used by Ashland and is defined by Ashland as earnings (loss) from continuing operations, adjusted for identified key items and divided by the number of outstanding diluted shares of common stock. Ashland believes this measure provides investors additional insights into operational performance by providing the earnings per share metric that excludes the effect of the identified key items.
Ashland Global Holdings Inc. (ASH ) is a premier global specialty chemicals company serving customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, automotive, construction, energy, food and beverage, personal care and pharmaceutical. At Ashland, we are nearly 7,000 passionate, tenacious solvers - from renowned scientists and research chemists to talented engineers and plant operators - who thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com to learn more.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "should," "plans" and "intends" and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the SEC, news releases and other written and oral communications. These forward-looking statements are based on Ashlands expectations and assumptions, as of the date such statements are made, regarding Ashlands future operating performance and financial condition, as well as the economy and other future events or circumstances. Ashlands expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the impact of acquisitions and/or divestitures Ashland has made or may make, including the acquisition of Pharmachem (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashlands substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashlands future cash flows, results of operations, financial condition and its ability to repay debt); the potential that Ashland does not realize all of the expected benefits of the separation of its Valvoline business; and severe weather, natural disasters, cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters). Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements, including, without limitation, risks and uncertainties affecting Ashland that are described in Ashlands most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashlands website at http://investor.ashland.com or on the SECs website at http://www.sec.gov . Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise. Information on Ashlands website is not incorporated into or a part of this news release.
(1) Preliminary Results
Financial results are preliminary until Ashlands Form 10-K is filed with the SEC.
(TM) Trademark, Ashland or its subsidiaries, registered in various countries.
FOR FURTHER INFORMATION:
Seth A. Mrozek
+1 (859) 815-3527
+1 (859) 815-3047
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ashland Inc. via Globenewswire
Q4 2017 Earnings release slides - FINAL - http://hugin.info/147920/R/2147616/823685.pdf
Q4 2017 Financial Tables - FINAL - http://hugin.info/147920/R/2147616/823683.xlsx